1-12 of 12
Christopher J Kirk, PhD
Close
Sort by
Journal Articles

Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies

Eric Lowe, BS, Andrea R Fan, PhD, Jing Jiang, Henry W. B. Johnson, PhD, Christopher J. Kirk, PhD, Dustin McMinn, PhD, Tony Muchamuel, MS, Yu Qian, PhD, Brian B. Tuch, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 408.
https://doi.org/10.1182/blood-2019-123782
Published: 2019
Journal Articles

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Yu Qian, PhD, Henry W.B. Johnson, PhD, Christopher J. Kirk, PhD, Eric Lowe, BS, Dustin McMinn, PhD, Beatriz Millare, BS, Tony Muchamuel, MS, Jinhai Wang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2076.
https://doi.org/10.1182/blood-2019-125988
Published: 2019
Journal Articles

Protein Translocation Inhibitors Overcome Cytokine-Induced Glucocorticoid Resistance in T-Cell Acute Lymphoblastic Leukemia

Lauren K. Meyer, Cristina Delgado-Martin, PhD, Phillip P. Sharp, PhD, Dustin McMinn, PhD, Christopher J. Kirk, PhD, Jack Taunton, PhD, Michelle L. Hermiston, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 805.
https://doi.org/10.1182/blood-2019-127537
Published: 2019
Journal Articles

A Method To Identify Copy Number Aberrations (CNAs) From Whole Exome Sequence (WES) Data and Its Application To Multiple Myeloma Cell Lines and Patient Samples

Jeremiah D Degenhardt, Ph.D., Kenneth B Hoehn, Kevin A Kwei, Ph.D., Jonathan J Keats, PhD, Christopher J. Kirk, PhD, Brian B Tuch, Ph.D.
Journal: Blood
Blood (2013) 122 (21): 4881.
https://doi.org/10.1182/blood.V122.21.4881.4881
Published: 2013
Journal Articles

Use of the Immunoproteasome Subunit LMP7 Inhibitor to Ameliorate Gvhd in an MHC-Matched miHA-Disparate Murine Model

Jenny Zilberberg, Ph.D., Eugenia Dziopa, Christopher J Kirk, PhD, Robert Korngold, PhD
Journal: Blood
Blood (2012) 120 (21): 4106.
https://doi.org/10.1182/blood.V120.21.4106.4106
Published: 2012
Journal Articles

Interferon-γ-Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harbouring Bortezomib-Induced Mutations in Constitutive PSMB5

Denise Niewerth, MSc, Niels Franke, MD, Gerrit Jansen, PhD, Yehuda Assaraf, PhD, Johan van Meerloo, MSc, Christopher J Kirk, PhD, Sonja Zweegman, MD, PhD, Gertjan J.L. Kaspers, MD, PhD, Jacqueline Cloos, PhD
Journal: Blood
Blood (2012) 120 (21): 1346.
https://doi.org/10.1182/blood.V120.21.1346.1346
Published: 2012
Journal Articles

Carfilzomib, An Irreversible Proteasome Inhibitor, Induces Long-Term Growth Inhibition of Mantle Cell Lymphoma In Vivo,

Liang Zhang, MD, PhD, Jianfei Qian, PhD, Zhishuo Ou, MD, Luhong Sun, MD, PhD, Kejie Zhang, MD, PhD, Lan V Pham, PhD, Christopher J Kirk, PhD, Richard J. Ford, MD, PhD, Qing Yi, MD, PhD, Michael Wang, MD
Journal: Blood
Blood (2011) 118 (21): 3740.
https://doi.org/10.1182/blood.V118.21.3740.3740
Published: 2011
Journal Articles

Potent Inhibition of Multiple Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients

Susan J Lee, Tina M Woo, Shirin Arastu-Kapur, PhD, Alvin F Wong, Pharm.D., Thomas E Renau, PhD, Christopher J Kirk, PhD
Journal: Blood
Blood (2011) 118 (21): 5068.
https://doi.org/10.1182/blood.V118.21.5068.5068
Published: 2011
Journal Articles

Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.

Suzanne Trudel, MD, Susan Lee, Christopher J. Kirk, PhD, Nashat Gabrail, MD, Sagar Lonial, MD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Vishal Kukreti, MD, FRCPC, A. Keith Stewart, MD, Sundar Jagannath, MD, Kevin T. McDonagh, MD, Francis Buadi, MD, Jeffrey A Zonder, MD, Mark K Bennett, PhD, The Multiple Myeloma Research Consortium (MMRC)
Journal: Blood
Blood (2009) 114 (22): 1845.
https://doi.org/10.1182/blood.V114.22.1845.1845
Published: 2009
Journal Articles

Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome.

Christopher J. Kirk, PhD, Monette A. Aujay, B.S., Mark Ho, B.S., Jing Jiang, B.S., Guy J. Laidig, Ph.D., Evan R. Lewis, Ph.D., Yan Lu, M.S., Tony Muchamuel, M.S., Tina M. Woo, B.S., Congcong M. Sun, M.S., Catherine Sylvain, Ph.D., Jinfu Yang, Ph.D., Han-jie Zhou, Ph.D., Mark K. Bennett, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 3581.
https://doi.org/10.1182/blood.V108.11.3581.3581
Published: 2006
Journal Articles

Metabolism, Disposition and Pharmacokinetics of PR-171, a Novel Inhibitor of the 20S Proteasome.

Jinfu Yang, PhD, Fabiana Fonseca, PhD, Mark Ho, BS, Christopher J. Kirk, PhD, Louis S. Sehl, PhD, Evan R. Lewis, PhD
Journal: Blood
Blood (2006) 108 (11): 5067.
https://doi.org/10.1182/blood.V108.11.5067.5067
Published: 2006
Journal Articles

Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.

Christopher J. Kirk, PhD, Mark K. Bennett, PhD, Tonia J. Buchholz, MS, Susan D. Demo, PhD, Mark N. Ho, BS, Jing Jiang, BS, Guy J. Laidig, PhD, Evan R. Lewis, PhD, Kevin D. Shenk, BS, Mark S. Smyth, PhD, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina M. Woo, BS, Christopher J. Molineaux, PhD
Journal: Blood
Blood (2005) 106 (11): 609.
https://doi.org/10.1182/blood.V106.11.609.609
Published: 2005